TRAW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Traws Pharma Inc is not a good buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive catalysts, has weak financial performance, and no strong trading signals. Analysts have optimistic price targets, but the company's fundamentals and technical indicators do not support an immediate investment.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 43.652, and moving averages are converging, showing no clear directional momentum. The stock is trading below the pivot level of 1.989, with support at 1.76 and resistance at 2.218.
Analysts have initiated coverage with Buy ratings and high price targets ($6.50 and $8), citing the company's promising pipeline of oral antivirals.
No recent news or significant trading trends. Financial performance is weak, with revenue at 0, net income down -64.19% YoY, and EPS down -96.14% YoY. Stock trend analysis shows a likelihood of minor declines in the short term.
In Q3 2025, the company reported a 100% drop in revenue, a net income loss of -$3,035,000 (-64.19% YoY), and an EPS decline of -96.14% YoY. Gross margin remained at 100%, but this is not meaningful given the lack of revenue.
Two analysts have initiated Buy ratings with price targets of $6.50 and $8, citing the potential of the company's antiviral pipeline. However, these targets are speculative and rely on successful development of the pipeline.
